| 4FOC: reference: The discovery and optimization of a novel class of potent, selective and orally bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with potential utility for the treatment of cancer., Lewis RT, Bode CM, Choquette D, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu V, Saffran DC, Xu M, Drew AE, Merkel P, Szilvassy S, Brake RL, J Med Chem. 2012 Jun 26. PMID: 22734674 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).